BUFFALO, N.Y., Dec. 16, 2022 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the exit of its 503B sterile compounding business. 503B product sales accounted for approximately 19% of Athenex’s total product sales in the third quarter of 2022.
Duos Enters Into 3-Year Agreement With CPKC, To Use Duos Developed Artificial Intelligence Solutions For Mechanical Inspections And Cross-Border Velocity And Efficiency
Duos Technologies Group, Inc. ("Duos" or the "Company") (NASDAQ:DUOT), through its operating subsidiary Duos Technologies, Inc., a provider of Machine Vision and Artificial Intelligence ("AI") to analyze fast moving
